Claims for Patent: 10,000,553

Summary for Patent: 10,000,553

Title:	CD40L-specific TN3-derived scaffolds and methods of use thereof
Abstract:	The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
Inventor(s):	Coyle; Anthony (Boston, MA), Baca; Manuel (Gaithersburg, MD), Thisted; Thomas (Gaithersburg, MD), Drabic; Stacey (Gaithersburg, MD), Grinberg; Luba (Gaithersburg, MD), Novarra; Shabazz (Gaithersburg, MD), Oganesyan; Vaheh (Gaithersburg, MD), Herbst; Ronald (Gaithersburg, MD), Spencer; David Kenneth (Gaithersburg, MD)
Assignee:	Viela Bio, Inc. (Gaithersburg, MD)
Application Number:	14/347,016
Patent Claims:	1. A Tn3 scaffold comprising a CD40L-specific monomer subunit, wherein the monomer subunit comprises seven beta strands designated A, B, C, D, E, F, and G, and six loop regions designated AB, BC, CD, DE, EF, and FG, wherein the AB loop comprises SEQ ID NO: 4, the BC loop comprises a sequence selected from the group consisting of SEQ ID NOs: 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, and 168, the CD loop comprises SEQ ID NO: 6, the DE loop comprises a sequence selected from the group consisting of SEQ ID NOs: 94, 95, 96, 97, 98, and 169, the EF loop comprises SEQ ID NO: 8, and the FG loop comprises a sequence selected from the group consisting of SEQ ID NOs: 9, 99, 139, and 170, and wherein the Tn3 scaffold specifically binds to CD40L. 2. The Tn3 scaffold of claim 1, comprising two CD40L-specific monomer subunits connected in tandem. 3. The Tn3 scaffold of claim 1, wherein the scaffold binds CD40L and prevents binding of CD40L to CD40 and/or disrupts CD40 mediated signaling. 4. The Tn3 scaffold of claim 2, wherein at least one CD40L-specific monomer subunit is fused or conjugated to a heterologous moiety selected from the group consisting of: a protein, a peptide, a protein domain, a linker, a drug, a toxin, a cytotoxic agent, an imaging agent, a radionuclide, a radioactive compound, an organic polymer, an inorganic polymer, a polyethylene glycol (PEG), biotin, an albumin, a human serum albumin (HSA), a HSA FcRn binding portion, an antibody, a domain of an antibody, an antibody fragment, a single chain antibody, a domain antibody, an albumin binding domain, an enzyme, a ligand, a receptor, a binding peptide, a non-FnIII scaffold, an epitope tag, a recombinant polypeptide polymer, and a cytokine. 5. The Tn3 scaffold of claim 4, wherein at least one CD40L-specific monomer subunit is conjugated to PEG or is fused to a human serum albumin (HSA). 6. The Tn3 scaffold of claim 5, wherein said HSA is a variant HSA having the amino acid sequence of SEQ ID NO: 133. 7. The Tn3 scaffold of claim 1, wherein the A beta strand consists of SEQ ID NO:11, the B beta strand consists of SEQ ID NO:12, the C beta strand consists of SEQ ID NO:13 or SEQ ID NO:14, the D beta strand consists of SEQ ID NO:15, the E beta strand consists of SEQ ID NO:16, the F beta strand consists of SEQ ID NO:17, and the G beta strand consists of SEQ ID NO:18. 8. The Tn3 scaffold of claim 1 comprising a sequence selected from the group consisting of: SEQ ID NOs: 134, 135, 144, 145, 146, 166, 205, 206, 207 and 208. 9. A method of altering CD40 mediated signaling comprising contacting a CD40L expressing cell with the Tn3 scaffold of claim 1, wherein the Tn3 scaffold binding CD40L and disrupts CD40 mediated signaling. 10. The method of claim 9, wherein the CD40 mediated signaling is a T-dependent immune response. 11. A composition comprising the Tn3 scaffold of claim 1 and a pharmaceutically acceptable excipient. 12. The Tn3 scaffold of claim 7, wherein: (a) the sequence of the BC loop comprises SEQ ID NO: 83, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; (b) the sequence of the BC loop comprises SEQ ID NO: 83, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 99; (c) the sequence of the BC loop comprises SEQ ID NO: 84, the sequence of the DE loop comprises SEQ ID NO: 95, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; (d) the sequence of the BC loop comprises SEQ ID NO: 85, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; (e) the sequence of the BC loop comprises SEQ ID NO: 86, the sequence of the DE loop comprises SEQ ID NO: 96, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; (f) the sequence of the BC loop comprises SEQ ID NO: 87, the sequence of the DE loop comprises SEQ ID NO: 97, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; (g) the sequence of the BC loop comprises SEQ ID NO: 88, the sequence of the DE loop comprises SEQ ID NO: 95, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; (h) the sequence of the BC loop comprises SEQ ID NO: 89, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; (i) the sequence of the BC loop comprises SEQ ID NO: 90, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; (j) the sequence of the BC loop comprises SEQ ID NO: 91, the sequence of the DE loop comprises SEQ ID NO: 95, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; (k) the sequence of the BC loop comprises SEQ ID NO: 92, the sequence of the DE loop comprises SEQ ID NO: 98, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; or, (l) the sequence of the BC loop comprises SEQ ID NO: 93, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139. 13. The Tn3 scaffold of claim 12, wherein the CD40L-specific monomer subunit comprises a sequence selected from the group consisting of SEQ ID NO: 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 and 146. 14. The Tn3 scaffold of claim 2, wherein the CD40L-specific monomer subunits are connected by a peptide linker. 15. The Tn3 scaffold of claim 14, wherein the peptide linker comprises a (GmX)n sequence wherein: (a) X is Serine (S), Alanine (A), Glycine (G), Leu (L), Isoleucine (I), or Valine (V); (b) m and n are integers; (c) m is 1, 2, 3 or 4; and (d) n is 1, 2, 3, 4, 5, 6, or 7. 16. The Tn3 scaffold of claim 15, wherein the peptide linker is selected from the group consisting of: SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 142, and SEQ ID NO: 143. 17. The Tn3 scaffold of claim 2, wherein the Tn3 scaffold comprises SEQ ID NO: 145. 18. The Tn3 scaffold of claim 5, wherein the CD40L-specific monomer subunit is conjugated to PEG or is fused to a human serum albumin (HSA) via a linker. 19. The Tn3 scaffold of claim 2, wherein the CD40L-specific monomer subunits comprise SEQ ID NO: 146.

Details for Patent 10,000,553

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	October 21, 1942		2031-10-11
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	March 03, 1954		2031-10-11
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	July 23, 1976		2031-10-11
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	August 15, 1978		2031-10-11
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	November 29, 2022		2031-10-11